Latest News

During his childhood in Wolcott, Conn., Karl Insogna’s parents instilled in him a few life lessons. Insogna, MD, FACP, Ensign Professor of Medicine (Endocrinology); director, Yale Bone Center; and associate director, Yale Center for X-Linked Hypophosphatemia; was taught to strive to leave the world a better place than you found it, and to do something to help others.

Yale Cancer Center physicians, scientists, and trainees from Yale School of Medicine present new findings at the 65th annual American Society for Radiation Oncology (ASTRO) meeting from October 1-4 in San Diego, California.

Drs. Garcia-Manero and Zeidan discuss the significance of efficacy and safety data from the COMMANDS trial in myelodysplastic syndrome, takeaways from the subgroup analyses, and expectations around treatment sequencing in the lower-risk population.

As a part of our “Meet Yale Internal Medicine” series, today’s feature is on Jacquelyne Gaddy, MD, Assistant Professor of Medicine (Medical Oncology).

There have been demonstrated differences in tumor cell metabolism between right-sided and left-sided colorectal tumors, which could explain the differences observed in their clinical behavior, especially in metastatic disease.

Daniel P. Petrylak, MD, discusses background and findings from the phase 3 KEYNOTE-921 study of pembrolizumab plus docetaxel vs placebo plus docetaxel in patients with metastatic castration-resistant prostate cancer who had received prior next-generation hormonal agent therapy.

The National Institutes of Health (NIH) and the U.S. Food and Drug Administration (FDA) have renewed a $20 million grant for the Yale Tobacco Center of Regulatory Science (TCORS). The Yale center is led by co-directors Suchitra Krishnan-Sarin, PhD, Albert E. Kent Professor of Psychiatry; and Stephanie O’Malley, PhD, Elizabeth Mears and House Jameson Professor of Psychiatry.

The use of lutetium 177Lu dotatate (Lutathera) and high-dose long-acting octreotide as frontline treatment for patients with newly diagnosed somatostatin receptor (SSTR)-positive, grade 2 and 3, advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) led to significant improvements in progression-free survival (PFS) compared with high-dose long-acting octreotide alone. "This would represent a new indication for first-line treatment of GEP-NETS. In addition, this would represent the first theranostic agent FDA approved for use in the 1st line setting," said Kunz, associate professor of Internal Medicine (Medical Oncology); director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center; chief, GI Medical Oncology; vice chief, Diversity, Equity, and Inclusion, Medical Oncology.

On September 21, 2023, a celebration was held in honor of Christina Holt, MSN, APRN (BC), ACHPN, OCN, who has been recognized by The Hastings Center and The Cunniff-Dixon Foundation for Outstanding End-of-Life Care.